NCT06586983
Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia
StatusActive, Not Recruiting
PhaseNot specified
SponsorOslo University Hospital
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 4 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Site details revised
- Collaborators: details revised at 1 of 4 entries
- Publications: details revised at 1 of 1 entry
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Death or liver decompensation
Timeframe: 3 years
Secondary (4)
Linkage to care
Loss to follow-up
Viral suppression
HIV incidence
Arms and interventions
Standard model ("treat only if")
HBsAg positive patients will be eligible for treatment of they fulfill one of the following criteria: i) Clinically diagnosed cirrhosis; or ii) APRI ≥0.5; or iii) Persistently elevated ALT \>40 U/L; or iv) Co-infection with HCV or HDV; or v) Family history of HCC/cirrhosis; or vi) Relevant co-morbidity
Inclusive model ("treat all except")
HBsAg positive patients will receive treatment, except if APRI ≤0.3 and no clinical signs/symptoms of cirrhosis and no risk factors for liver disease.
Test-and-treat model ("treat all")
All HBsAg positive patients will receive treatment.
Drugs: Tenofovir Disoproxil Fumarate
Sites
1 site in 1 country
- Addis Ababa UniversityAddis Ababa, Addis Ababa, Ethiopia